NCT06670105

A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical research study is to learn if glofitamab can help to prevent recurrence of LBCL in patients who have achieved CR after standard first-line therapy but have tested positive for MRD. The safety of glofitamab will also be studied.

Detailed description

Primary Objective: To determine the rate of undetectable MRD following treatment with glofitamab in patients with LBCL who were MRD positive at the end of standard first line treatment Secondary Objective: To determine progression-free survival (PFS), overall survival (OS), and evaluate safety of glofitamab as treatment for patients with LBCL who are MRD positive at end of standard first line treatment Exploratory Objective: To determine the biomarkers of response and mechanisms of resistance to glofitamab in LBCL To determine the kinetics of T-cell activation and exhaustion in patients treated with gofitamab to eliminate MRD

Conditions

• B-cell Lymphoma

Interventions

Type	Name	Description
DRUG	Glofitamab	Given by vein

Timeline

• Start date: 2025-06-06
• Primary completion: 2030-01-06
• Completion: 2032-01-06
• First posted: 2024-11-01
• Last updated: 2025-09-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study